Current report No. 6/2023 – Allocation of A-series subscription warrants to eligible persons under the Incentive Program for Members of the Management Board of the Company for 2022

Date prepared: April 25, 2023

Abbreviated name of the issuer: CELON PHARMA S.A.

Subject: Allocation of A-series subscription warrants to eligible persons under the Incentive Program for Members of the Management Board of the Company for 2022

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

The Management Board of Celon Pharma S.A. (“Company”) wishes to announce that on April 25, 2023, the Company's Supervisory Board has adopted a resolution on allocation of in total of 21,500 A-series subscription warrants (“Warrants”) to individuals who in 2022 acted as members of the Company's Management Board, as part of the Incentive Program. Each Warrant entitles its holder to subscribe for 1 C-series share of the Company at the issue price of PLN 0.10 per share. The Warrants are issued on the basis of Resolution No. 7/2021 of the Extraordinary General Meeting of the Company of February 16, 2021 on the issue, for the purpose of implementing Incentive Programs for Members of the Management Board and other persons of key importance to the Company, of A-series subscription warrants with exclusion of share subscription rights of existing shareholders, entitling them to subscribe for C-series shares and a conditional increase of the share capital through the issue of C-series shares with exclusion of share subscription rights of existing shareholders and an amendment to the Company's Articles of Association related thereto.

The Warrants were allocated on the basis of Resolution No. 6 adopted by the Extraordinary General Meeting of the Company of February 16, 2030 on the introduction of Incentive Programs for Members of the Management Board and other persons of key importance to the Company and on the basis of the Regulations of the Incentive Program for the Members of the Management Board for the years 2021-2030 in Celon Pharma S.A. (see current report No. 44/2021), in connection with the approval by the Company's Supervisory Board of fulfilling a part of the management objectives determined in accordance with the provisions of the aforementioned Regulations.